AbbVie, ChanRx, Enanta, Gilead, Merck, Sanofi
ChanRx posts positive A-Fib data . . . read more
AbbVie, Enanta show HCV results . . . read more
Gilead gets EC approval for Vitekta . . . read more
Merck's Noxafil IV gets priority review . . . read more
Sanofi ends JAK2 development . . . read more
Sign up now to receive the free weekly newsletter, and more!
The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.